News We’re Watching – FDA Nixes Neuralink Trials, Layoffs at J&J, Novel Knee Implants
Executive Summary
This week, we learned that the US FDA thinks Elon Musk’s Neuralink brain interface device isn’t ready for human trials. Additionally, J&J cut about 300 medtech jobs, Stryker launched a knee implant, and Active Implants’ meniscus replacement device made it to the FDA’s advisory panel calendar.
You may also be interested in...
After Two-Year Delay, J&J Plans To Start Trial Ottava Surgical Robot In 2024
J&J originally projected its Ottava soft-tissue robotic surgery system would enter first-in-human trials in 2022 and reach the market by 2023, but the development has been delayed by technical challenges and COVID-19-related disruptions. Now the company plans to start trials of a four-armed version of the device in about a year.
FDA Face Mask Guidance Updated To Reflect End Of PHE
A revised guidance for face masks and barrier face coverings changes the language of the title and text to reflect the end of the PHE.
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.